Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Nanostar Biosensors Use Raman Scattering for Direct Detection of Cancer-Related MicroRNAs

By LabMedica International staff writers
Posted on 03 Aug 2020
A novel non-invasive nanoparticle-based assay detects cancer-related microRNAs without use of labels or target amplification.

MicroRNAs (miRNAs) comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. More...
With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. In addition to miRNAs playing an essential role in tumor development, dysregulation of certain miRNAs has been associated with many different diseases, such as dementia, and cardiovascular conditions. However, due to technical difficulties in detecting these small molecules, miRNAs have not been adopted into routine clinical practice for early diagnostics. Thus, it is important to develop alternative detection strategies that could offer more advantages over conventional methods.

In this regard, investigators at Duke University (Durham, NC, USA) developed nanophotonics technology termed "the inverse molecular sentinel (iMS) nanobiosensor, with surface-enhanced Raman scattering (SERS) detection".

The iMS-SERS technique is based on plasmonics, which refers to the enhanced electromagnetic properties of metallic nanostructures. The term plasmonics is derived from "plasmons", which are the quanta associated with longitudinal waves propagating in matter through the collective motion of large numbers of electrons. Incident light, usually from a laser, irradiating these surfaces excites conduction electrons in the metal, and induces excitation of surface plasmons leading to enormous electromagnetic enhancement of spectral signature, such as surface-enhanced Raman scattering (SERS) and surface-enhanced fluorescence (SEF) for ultrasensitive detection of chemical and biological species.

The SERS nanoprobe used in the current study relied on plasmonic-active nanostars as the sensing platform. An “OFF-to-ON” signal switch was based on a nonenzymatic strand-displacement process and the conformational change of stem-loop (hairpin) oligonucleotide probes upon target binding. This technique was used previously to detect a synthetic DNA sequence of interest. In this study, the design of the nanoprobe was modified to be used for the detection of short miRNA sequences.

In the current study, the investigators found that the iMS-SERS nanostar method detected miR-21, the microRNA biomarker linked to esophageal adenocarcinoma (EAC) and Barrett's esophagus (BE), the premalignant metaplasia associated with EAC. This approach enabled the direct detection of the esophageal cancer biomarker in RNA extracted from 17 endoscopic tissue biopsies. Thus, the potential of this label-free, homogeneous biosensor for cancer diagnosis without the need for target amplification was demonstrated by discriminating esophageal cancer and Barrett's esophagus from normal tissue with notable diagnostic accuracy.

"Gold nanostars have multiple spikes that can act as lighting rods for enhancing electromagnetic waves, which is a unique feature of the particle's shape," said senior author Dr. Tuan Vo-Dinh, professor of biomedical engineering at Duke University. "Our tiny nanosensors, called "inverse molecular sentinels", take advantage of this ability to create clear signals of the presence of multiple microRNAs. The Raman signals of label molecules exhibit sharp peaks with very specific colors like spectral fingerprints that make them easily distinguished from one another when detected. Thus we can actually design different sensors for different microRNAs on nanostars, each with label molecules exhibiting their own specific spectral fingerprints. And because the signal is so strong, we can detect each one of these fingerprints independently of each other."

"The general research focus in my lab has been on the early detection of diseases in people before they even know they are sick," said Dr.Vo-Dinh. "And to do that, you need to be able to go upstream, at the genomic level, to look at biomarkers like microRNA."

The gold nanostar paper was published in the May 4, 2020, online edition of the journal Analyst.

Related Links:
Duke University


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pan-Cancer Panel
TruSight Oncology 500
New
Automated Microscope
dIFine
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.